Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including mRNA, siRNA, replicon RNA, asRNA, DNA, and gene editing therapeutics.

Meanwhile Arcturus, a San Diego biotech working with messenger RNA (mRNA) therapies said it is working with Duke-NUS Medical School (Duke-NUS) to develop a coronavirus vaccine for Singapore.

São Paulo's Municipal Health Secretariat reported this week the first case of variant XBB.1.16 of Covid-19, also known as Arcturus in a 75-year-old man, bedridden and with comorbidities ...

About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...

The Ministry of Health, Labour and Welfare (MHLW) gave the green light to CSL and Arcturus’ COVID-19 vaccine ARCT-154 – also known as Lunar-COV19 – which will be commercialised in Japan by ...

In this article, we are going to take a look at where Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stands against other worst high-risk high-reward growth stocks to buy. On March 14 ...

Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate. Arcturus on Thursday said the designation ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...